Excellence In Peripheral Artery Disease Thrombin Receptor Antagonist Intervention In Claudication Evaluation (XLPAD-TRACE Trial)
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.
Also called NCT02660866
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 200 participants
- Registry
-
NCT02660866
-
- Other papers using this trial's data
- No benefit of vorapaxar on walking performance in patients with intermittent claudication
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Unknown status
Technical summary
Registry record NCT02660866. Randomized; quadruple masking; primary purpose treatment. Start 2016-07 (registry gives no type); primary completion 2019-07 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Excellence In Peripheral Artery Disease Thrombin Receptor Antagonist Intervention In Claudication Evaluation (XLPAD-TRACE Trial)
- Acronym
- XLPADTRACE
- Condition
- Peripheral Arterial Disease
- Intervention (Drug)
- Placebo + background APT + SMT
- Intervention (Drug)
- Vorapaxar 2.08 mg/d + background APT + SMT.
- Lead sponsor
- North Texas Veterans Healthcare System
Record details
- Record id
cardio:ct-nct02660866- Content hash
05a5ac189da127f481fb92c521069e359a53456d2136972f389783e228866638